PARP Inhibitors Resistance: Mechanisms and Perspectives

38Citations
Citations of this article
93Readers
Mendeley users who have this article in their library.

Abstract

Simple Summary: This review aims to analyze the emerging issue regarding PARP inhibitor’s resistance in tumors and their consequence on disease prognosis and treatment. Besides, we evaluate possible strategies and new therapeutic approaches to overcome PARPis resistance. Abstract: PolyADP-ribose polymerase (PARP) inhibitors (PARPis) represent the first clinically approved drugs able to provoke “synthetic lethality” in patients with homologous recombination-deficient (HRD) tumors. Four PARPis have just received approval for the treatment of several types of cancer. Besides, another three additional PARPis underlying the same mechanism of action are currently under investigation. Despite the success of these targeted agents, the increasing use of PARPis in clinical practice for the treatment of different tumors raised the issue of PARPis resistance, and the consequent disease relapse and dismal prognosis for patients. Several mechanisms of resistance have been investigated, and ongoing studies are currently focusing on strategies to address this challenge and overcome PARPis resistance. This review aims to analyze the mechanisms underlying PARPis resistance known today and discuss potential therapeutic strategies to overcome these processes of resistance in the future.

References Powered by Scopus

Olaparib for metastatic breast cancer in patients with a germline BRCA mutation

2347Citations
N/AReaders
Get full text

Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer

1982Citations
N/AReaders
Get full text

PARP inhibitors: Synthetic lethality in the clinic

1892Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment

16Citations
N/AReaders
Get full text

Mechanisms of PARP-Inhibitor-Resistance in BRCA-Mutated Breast Cancer and New Therapeutic Approaches

14Citations
N/AReaders
Get full text

Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Giudice, E., Gentile, M., Salutari, V., Ricci, C., Musacchio, L., Carbone, M. V., … Lorusso, D. (2022, March 1). PARP Inhibitors Resistance: Mechanisms and Perspectives. Cancers. MDPI. https://doi.org/10.3390/cancers14061420

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 17

81%

Researcher 3

14%

Professor / Associate Prof. 1

5%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 14

56%

Agricultural and Biological Sciences 6

24%

Chemistry 3

12%

Medicine and Dentistry 2

8%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free